Faculty

Connie Celum

Adjunct Professor, Epidemiology
Professor, Global Health
Professor, Medicine - Allergy and Infectious Dis.
Director, International Clinical Research Center (ICRC), Global Health


Education

MD Medicine, University of California (San Francisco), 1984
MPH Epidemiology, University of Washington, 1989

Contact


Box 359927
University of Washington
Seattle, WA
University of Washington
Box 359927
Allergy and Infectious Diseases
Seattle, WA 98195

Research Interests

Dr. Celum's research currently focuses on HIV prevention and vaccine trials with the objective to find effective strategies to reduce HIV acquisition and transmission. She utilizes epidemiologic data on behavioral and biologic risk factors for HIV acquisition and transmission to identify potential intervention strategies and then to conduct randomized clinical trials to determine safety and efficacy of these interventions with biologic outcome measurements. Her current effort is focused on sexually transmitted diseases (STDs), particularly genital herpes, as co-factors for HIV acquisition and transmission and clinical trials of candidate HIV vaccines. First, she is investigating HSV-2 as a co-factor for HIV acquisition and transmission, through a large randomized trial of daily antivirals for HSV-2 suppression to determine whether HIV acquisition can be reduced by 50% among HIV-negative, HSV-2 seropositive women in two African sites, and among MSM in Peru and two US sites. Second, to determine the effect of genital herpes on HIV infectiousness, she is conducting a large multi-center trial of HSV-2 suppression among HIV-discordant couples in Africa and India. Third, she is studying the effect of HSV-2 on mucosal HIV shedding with a double-blind cross-over study of valacyclovir among HIV/HSV-2 co-infected men and women in Peru. Fourth, she is studying the prevalence, incidence and risk factors for HSV-1 and HSV-2 acquisition among high-risk men who have sex with men in a multi-center trial of a behavioral intervention (Project Explore). Fifth, as part of her interest in the evaluation of HIV vaccine trials, she is developing approaches to assess the effect of partially-effective HIV vaccines on viral set-point and disease progression, including a standardized approach to provision of antiretroviral therapy for breakthrough infections in phase III trials.

Dr. Celum has developed research clinical units in Seattle and Lima, Peru, to conduct epidemiologic studies and clinical trials of HIV prevention interventions and vaccines. In addition, she serves as the PI on two multi-center international clinical trials of HSV-2 suppression and HIV transmission with sites in Africa, India, and Latin America, which provide opportunities for graduate students interested in studying the epidemiology of STD and HIV infection

HIV prevention; microbicide; vaccine trials with the objective to find effective strategies to reduce HIV acquisition and transmission.

Recent Publications (PubMed)

Acceptability of and confidence in novel tuberculosis vaccines among South African adults living with HIV.
(2026 Jul 14)
medRxiv
Giovanatti A, Sithole N, Govender I, Larson HJ, Lebina L, Drain PK, Celum C, McClelland RS, Ross JM, Grant AD, Shapiro AE

Doxycycline Resistance and 16S rRNA Mutations in Treponema pallidum.
(2026 Aug)
Emerg Infect Dis 32(8): 1384-1385
Beale MA, Marks M, Luetkemeyer A, Celum C, Golden MR, Giacani L, Lieberman NAP

Acceptability and use of doxyPEP among cisgender men who have sex with men, transgender women and non-binary persons assigned male sex at birth: results from a national online survey from the USA.
(2026 Jul 2)
Sex Transm Infect
Gistand NL, Torres TS, Celum C, Luetkemeyer A, Buchbinder S, Scott HM

Men's preferences for HIV self-test distribution strategies in Uganda: A discrete choice experiment.
(2026 Jun 26)
J Acquir Immune Defic Syndr
Bhardwaj S, Mugisha J, Magembe J, Eram G, Nakyanzi A, Mujugira A, Saldarriaga EM, Chen Y, Celum C, Terris-Presholt F, Sharma M

Pre-Human Immunodeficiency Virus (HIV) infection Th17 CD4+ T cells as predictors of early HIV disease progression.
(2026 Apr)
PLoS Pathog 22(4): e1013852
Omole TE, Nguyen HM, Marcinow A, Jahan N, Severini G, Naicker N, Thomas K, Celum C, Mugo N, Mujugira A, Kublin J, Corey L, Sivro A, Lingappa J, Gray G, McKinnon LR

Show complete publication list